CVS Health (CVS) is maintaining Thursday gains ahead of the closing bell after outpacing top and bottom line expectations, paired with a positive full-year outlook for 2025.

Yahoo Finance senior health reporter Anjalee Khemlani joins the Market Domination in breaking down the pharmacy chain's reaction to Medicare Advantage costs and its formulary deal with GLP-1 weight-loss drug developer Novo Nordisk (NVO). She highlights comments from CVS CEO David Joyner on the Novo Nordisk deal.

Jefferies equity research analyst Brian Tanquilut explained to Yahoo Finance why it is looking like a "new day" for CVS on these earnings and guidance prints.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here.